Renin–angiotensin–aldosterone system (RAAS) blockers (ACEI and ARBs) reduce ACR and the progression of DKD to more advanced stages, regardless of the blood pressure effect [85, 91, 92]. This evidence concerns the gene REN and diabetic kidney disease.